Niceritrol (BioDeep_00000181658)
human metabolite blood metabolite
代谢物信息卡片
3-(Pyridine-3-carbonyloxy)-2,2-bis[(pyridine-3-carbonyloxy)methyl]propyl pyridine-3-carboxylic acid
化学式: C29H24N4O8 (556.1594064)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 80%
分子结构信息
SMILES: C1=CC(=CN=C1)C(=O)OCC(COC(=O)C2=CN=CC=C2)(COC(=O)C3=CN=CC=C3)COC(=O)C4=CN=CC=C4
InChI: InChI=1S/C29H24N4O8/c34-25(21-5-1-9-30-13-21)38-17-29(18-39-26(35)22-6-2-10-31-14-22,19-40-27(36)23-7-3-11-32-15-23)20-41-28(37)24-8-4-12-33-16-24/h1-16H,17-20H2
描述信息
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AD - Nicotinic acid and derivatives
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98151 - Niacin-based Antilipidemic Agent
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents
D009676 - Noxae > D000963 - Antimetabolites
同义名列表
10 个代谢物同义名
3-(Pyridine-3-carbonyloxy)-2,2-bis[(pyridine-3-carbonyloxy)methyl]propyl pyridine-3-carboxylic acid; 3-(pyridine-3-carbonyloxy)-2,2-bis[(pyridine-3-carbonyloxy)methyl]propyl pyridine-3-carboxylate; Tetranicotinate, pentaerythritol; Pentaerythritol tetranicotinate; Tetrahydrochloride, niceritrol; Pentaerythritoltetranicotinate; Niceritrol tetrahydrochloride; Niceritrol; Perycit; bufor
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:31903
- PubChem: 4476
- HMDB: HMDB0255580
- DrugBank: DB13441
- ChEMBL: CHEMBL1697762
- Wikipedia: Niceritrol
- MeSH: Niceritrol
- CAS: 5868-05-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
Cell reports.
2021 04; 35(4):109040. doi:
10.1016/j.celrep.2021.109040. [PMID: 33910017] - Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - Hiroko Hamatani, Keiju Hiromura, Keiko Kobatake, Hiroaki Yoshida, Satsuki Kobayashi, Naohiro Yoneda, Ken Kayakabe, Takayuki Matsumoto, Takashi Kuroiwa, Kazue Ueki, Yoshihisa Nojima. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.
Clinical and experimental nephrology.
2010 Dec; 14(6):619-24. doi:
10.1007/s10157-010-0333-9. [PMID: 20842518] - Andrew G Bostom. Binder blinders-niacin of omission?.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2010 Apr; 55(4):628-30. doi:
10.1053/j.ajkd.2009.12.015. [PMID: 20079958] - V S Kamanna, S H Ganji, M L Kashyap. The mechanism and mitigation of niacin-induced flushing.
International journal of clinical practice.
2009 Sep; 63(9):1369-77. doi:
10.1111/j.1742-1241.2009.02099.x. [PMID: 19691622] - Yoshihiro Kiya, Shin-ichiro Miura, Bo Zhang, Hidenori Urata, Keijiro Saku. Effect of levothyroxine on total lipid profiles as assessed by analytical capillary isotachophoresis in a patient with hypothyroidism.
Endocrine journal.
2006 Dec; 53(6):865-8. doi:
10.1507/endocrj.k05-181. [PMID: 17001111] - Takayuki Fujioka, Takahiro Ueno, Taro Matsumoto, Hideyuki Watanabe. [Dyslipidemia in renal failure].
Nihon rinsho. Japanese journal of clinical medicine.
2004 Jun; 62 Suppl 6(?):118-23. doi:
NULL. [PMID: 15250280] - Akira Owada, Shin Suda, Toshihiko Hata. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial.
The American journal of medicine.
2003 Apr; 114(5):347-53. doi:
10.1016/s0002-9343(02)01567-x. [PMID: 12714122] - Norio Ieiri, Osamu Hotta, Yoshio Taguma. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2003 Jan; 41(1):244-9. doi:
10.1053/ajkd.2003.50016. [PMID: 12500244] - M Kinoshita, Y Mikuni, M Kudo, M Mori, E Horie, T Teramoto, T Matsushima. The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia.
The Journal of international medical research.
2002 May; 30(3):271-81. doi:
10.1177/147323000203000308. [PMID: 12166344] - H Wakasugi, T Futami, E Muso, T Ono, S Sasayama, K Inui. Thrombocytopenia and anemia induced by niceritrol used for amelioration of hyperphosphatemia in a hemodialysis patient.
Nephron.
2000 Sep; 86(1):97-8. doi:
10.1159/000045722. [PMID: 10971163] - Y Nishizawa, T Shoji, T Tabata, T Inoue, H Morii. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients.
Kidney international. Supplement.
1999 Jul; 71(?):S134-6. doi:
10.1046/j.1523-1755.1999.07133.x. [PMID: 10412757] - Y Saika, N Kodama, K Kimura, R Fujii, H Ohtani, M Mune, K Mimura, T Maeda, S Yukawa. [Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol].
Nihon Jinzo Gakkai shi.
1999 Jun; 41(4):430-5. doi:
NULL. [PMID: 10441992] - N Kuboyama, Y Watanabe, M Yamaguchi, K Sato, T Suzuki, T Akiba. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
1999 Mar; 14(3):610-4. doi:
10.1093/ndt/14.3.610. [PMID: 10193807] - K Shimoda, T Akiba, T Matsushima, T Rai, K Abe, M Hoshino. [Niceritrol decreases serum phosphate levels in chronic hemodialysis patients].
Nihon Jinzo Gakkai shi.
1998 Jan; 40(1):1-7. doi:
NULL. [PMID: 9513376] - K Tanaka, K Hayashi, T Shingu, Y Kuga, Y Okura, Y Yasunobu, H Ohtani, S Nomura, H Kurushima, M Saeki, M Kambe, G Kajiyama. Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels.
Metabolism: clinical and experimental.
1997 Apr; 46(4):355-8. doi:
10.1016/s0026-0495(97)90046-9. [PMID: 9109834] - T Shoji, Y Nishizawa, K Kawasaki, T Tabata, Y Matsushita, T Inoue, H Morii. Effects of the nicotinic acid analogue niceritrol on lipoprotein Lp(a) and coagulation-fibrinolysis status in patients with chronic renal failure on hemodialysis.
Nephron.
1997; 77(1):112-3. doi:
10.1159/000190257. [PMID: 9380227] - T Teramoto, N Yamada, H Shimano, Y Oka, H Itakura, Y Saito, N Morisaki, K Shirai, T Ishikawa, N Tada, H Ito, T Yamanouchi, T Matsushima, M Kawakami, T Murase, M Okubo, Y Totsuka, M Kikuchi. Dose-dependent effect of niceritrol on plasma lipoprotein-a.
Scandinavian journal of clinical and laboratory investigation.
1996 Jul; 56(4):359-65. doi:
10.3109/00365519609090588. [PMID: 8837243] - H Suefuji, H Ogawa, H Yasue, N Imoto, T Sakamoto, Y Miyao, K Kaikita, H Soejima, K Nishiyama. Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
Coronary artery disease.
1996 Feb; 7(2):167-72. doi:
10.1097/00019501-199602000-00012. [PMID: 8813450] - N Hotta, J Nakamura, H Kakuta, H Fukasawa, N Koh, F Sakakibara, K Mori, N Sakamoto. Niceritrol prevents the decrease in red blood cell 2,3-diphosphoglycerate and neuropathy in streptozotocin-induced diabetic rats.
Journal of diabetes and its complications.
1995 Jul; 9(3):133-9. doi:
10.1016/1056-8727(95)00049-8. [PMID: 7548976] - J Sasaki, K Yamamoto, S Kobori, Y Setoguchi, Y Sato, A Matsunaga, M Shichiri, T Sakai, S Kono, K Arakawa. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
International journal of clinical pharmacology and therapeutics.
1995 Jul; 33(7):420-6. doi:
NULL. [PMID: 7582401] - S Takahashi, T Yamamoto, Y Moriwaki, Z Tsutsumi, K Higashino. Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.
Annals of the rheumatic diseases.
1995 Feb; 54(2):90-3. doi:
10.1136/ard.54.2.90. [PMID: 7702412] - K Yamauchi, Y Tanahashi, M Okada, J Tsuzuki, A Sato, K Abe, H Inagaki, H Agetsuma, R Hattori, H Izawa. Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a).
Clinical therapeutics.
1995 Jan; 17(1):52-9. doi:
10.1016/0149-2918(95)80006-9. [PMID: 7758061] - S A Spinler, M J Cziraky. Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy.
The Annals of pharmacotherapy.
1994 Mar; 28(3):343-51. doi:
10.1177/106002809402800310. [PMID: 8193425] - R Sano, A Fujino, T Saito, K Takenaka, Y Yahata, A Ogyu, T Toyota. Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease.
The Tohoku journal of experimental medicine.
1993 Apr; 169(4):299-307. doi:
10.1620/tjem.169.299. [PMID: 8248919] - H Nakahama, T Nakanishi, O Uyama, M Sugita, M Miyazaki, T Yokokawa, K Okamura, Y Tanaka, D Shirai. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.
Renal failure.
1993; 15(2):189-93. doi:
10.3109/08860229309046151. [PMID: 8469786] - A Matsunaga, K Handa, T Mori, K Moriyama, K Hidaka, M Yuki, J Sasaki, K Arakawa. Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.
Atherosclerosis.
1992 Jun; 94(2-3):241-8. doi:
10.1016/0021-9150(92)90249-g. [PMID: 1385959] - N Hotta, H Kakuta, H Fukasawa, N Koh, F Sakakibara, H Komori, N Sakamoto. Effect of niceritrol on streptozocin-induced diabetic neuropathy in rats.
Diabetes.
1992 May; 41(5):587-91. doi:
10.2337/diab.41.5.587. [PMID: 1533192] - K Mimura, S Yukawa. [Hyperlipidemia and drug treatment].
Nihon rinsho. Japanese journal of clinical medicine.
1991 Dec; 49 Suppl(?):781-6. doi:
NULL. [PMID: 1808350] - K Yamamoto, N Fukushima, I Ozaki, Y Setoguchi, T Yanagita, T Sakai. New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia.
Artery.
1991; 18(3):133-49. doi:
NULL. [PMID: 2069518] - R H Jay, A C Dickson, D J Betteridge. Effects of aspirin upon the flushing reaction induced by niceritrol.
British journal of clinical pharmacology.
1990 Jan; 29(1):120-2. doi:
10.1111/j.1365-2125.1990.tb03611.x. [PMID: 2297456] - L D Curtis, J P Reckless, A F Winder, D J Betteridge. Clinical and laboratory responses to niceritrol in the treatment of hypercholesterolaemia.
Postgraduate medical journal.
1988 Sep; 64(755):672-5. doi:
10.1136/pgmj.64.755.672. [PMID: 3075043] - S Nozaki, S Kihara, M Kubo, K Kameda, Y Matsuzawa, S Tarui. Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing.
International journal of clinical pharmacology, therapy, and toxicology.
1987 Dec; 25(12):643-7. doi:
NULL. [PMID: 3481359] - L Jacobsson. [Experimental hyperlipoproteinemia and arteriosclerosis in minipigs--effect of various drugs].
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete.
1986 Jul; 41(14):387-91. doi:
NULL. [PMID: 3532591] - Y Nagakawa, H Orimo, M Harasawa. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect.
Thrombosis research.
1985 Nov; 40(4):543-53. doi:
10.1016/0049-3848(85)90291-9. [PMID: 4082125] - T Hamazaki, K Hasunuma, S Kobayashi, H Shishido, S Yano. The effects on lipids, blood viscosity and platelet aggregation of combined use of niceritrol (Perycit) and a low dose of acetylsalicylic acid.
Atherosclerosis.
1985 Apr; 55(1):107-13. doi:
10.1016/0021-9150(85)90170-4. [PMID: 4004983] - L T Ho, J C Chern, S C Hsu, R L Chen, C F Kwok, M S Wu, J J Chen, T S Jap. The antilipemic effectiveness of pentaerythritol tetranicotinate on hyperlipidemic patients with or without diabetes mellitus--a double-blind, randomized and two-period change-over experiment.
Proceedings of the National Science Council, Republic of China. Part B, Life sciences.
1985 Jan; 9(1):20-9. doi:
NULL. [PMID: 3916369] - K Shirai, Y Ishikawa, T Nishide, N Sasaki, S Murano, A Sato, N Matsuoka, Y Saito, S Yoshida. Effect of niceritrol on lipid metabolism of aorta in atherosclerotic rats.
The Tohoku journal of experimental medicine.
1984 Jun; 143(2):231-8. doi:
10.1620/tjem.143.231. [PMID: 6474452] - A Subissi, M Criscuoli, M Biagi, W Murmann. Acute effects on plasma lipids in the rat of a new long-acting nicotinic acid derivative: LG 13979.
The Journal of pharmacy and pharmacology.
1983 Sep; 35(9):571-5. doi:
10.1111/j.2042-7158.1983.tb04335.x. [PMID: 6138406] - H Lithell, B Vessby, K Hellsing. Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol.
Atherosclerosis.
1982 Jun; 43(2-3):177-84. doi:
10.1016/0021-9150(82)90020-x. [PMID: 7052096] - K Oida, T Nakai, T Tamai, Y Kutsumi, T Kobayashi, T Hayashi, S Yamada, R Takeda. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
Artery.
1982; 10(4):266-85. doi:
NULL. [PMID: 7181672] - K Takikawa, K Miyazaki, T Arita. The behavior of pentaerythritol tetranicotinate in rat gastrointestinal tract as a prodrug.
Journal of pharmacobio-dynamics.
1981 Feb; 4(2):123-30. doi:
10.1248/bpb1978.4.123. [PMID: 7277198] - M Kibata, M Ishida, K Asano, H Uehara, K Saito, T Fuchimoto, K Ugaki, H Murakami, K Matoba, Y Kotakemori, K Shirai, H Yoshioka, M Nanba, M Yasuda, M Ishizaki, N Kitagawa, K Ikejiri, R Inohara, B J Lee, S Saino, J Sakado, H Matuzaka, K Numata, M Mandai, K Miyake, K Nakamura. Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.
Atherosclerosis.
1980 Nov; 37(3):333-42. doi:
10.1016/0021-9150(80)90137-9. [PMID: 7458980] - B Vessby, H Lithell, I B Gustafsson, J Boberg. Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
Atherosclerosis.
1980 Jan; 35(1):51-65. doi:
10.1016/0021-9150(80)90027-1. [PMID: 6989377] - B Vessby, H Lithell, I B Gustafsson, J Borberg. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Atherosclerosis.
1979 Aug; 33(4):457-77. doi:
10.1016/0021-9150(79)90038-8. [PMID: 228684] - L Harthon, R Brattsand. Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues.
Arzneimittel-Forschung.
1979; 29(12):1859-62. doi:
NULL. [PMID: 546424] - R Testa, M Gambini, C Canestrini. Comparison of plasma levels of free nicotinic acid in rats and rabbits treated with nicotinic acid, pentaerythritol tetranicotinate (Perycit) and 2,6-pyridine dimethanol dinicotinoate.
Il Farmaco; edizione pratica.
1978 Nov; 33(11):463-71. doi:
NULL. [PMID: 750231] - G R Ziliotto, G Lamberti, A Wagner, L Cima, G Genco. [Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial].
Archivio per le scienze mediche.
1977 Oct; 134(4):359-94. doi:
". [PMID: 345998] - T Katayama, J Shimazaki. [Effects of chlormadinone acetate therapy of prostatic neoplasms on liver functions, total serum cholesterol and triglycerides].
Horumon to rinsho. Clinical endocrinology.
1977 Apr; 25(4):411-4. doi:
NULL. [PMID: 68841] - S Rössner, A G Olsson, L Orö. The effects of different dose regimens of niceritrol of serum lipid concentrations in man.
Acta medica Scandinavica.
1976; 200(4):269-71. doi:
10.1111/j.0954-6820.1976.tb08230.x. [PMID: 983794] - P F Hansen. Differential drug therapy of the hyperlipoproteinaemias. The efficacy of lipid lowering drugs alone and in combination.
Postgraduate medical journal.
1975; 51(8):suppl 63-5. doi:
NULL. [PMID: 1052927] - L Orö, A G Olsson, S Rössner, L A Carlson. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
Postgraduate medical journal.
1975; 51(8):suppl 76-81. doi:
. [PMID: 215986]